Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
ORIA was delisted on the 28th of April, 2023.
41 hedge funds and large institutions have $127M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
17% more funds holding
Funds holding: 35 → 41 (+6)
13% more capital invested
Capital invested by funds: $112M → $127M (+$14.6M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
+$6.79M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$4.85M |
| 3 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
+$4.85M |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$4.75M |
| 5 |
Millennium Management
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIG
Fortress Investment Group
New York
|
-$5.03M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$2.92M |
| 3 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$933K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$877K |
| 5 |
DCM
DG Capital Management
New York
|
-$459K |
ORIA Hedge Fund Activity: Q1 2022 in Review
41 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q1 2022, worth a combined $127M — up 13% from $112M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORIA positions and 2 closed out — a net gain of 6 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Linden Advisors, opening a new position worth an estimated $6.79M. The largest seller was Fortress Investment Group, exiting entirely with an estimated $5.03M sold.
- 41 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q1 2022, up from 35 in Q4 2021.
- Funds reported $127M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q1 2022, up 13% quarter-over-quarter.
- 8 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q1 2022 and 2 closed out, a net change of +6 holders.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q1 2022 was Linden Advisors, an estimated $6.79M added.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q1 2022 was Fortress Investment Group, an estimated $5.03M sold.
Based on aggregated 13F filings for Q1 2022.